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Abstract: Phosphorylation events catalyzed by protein kinases represent one of the most prevalent
as well as important regulatory posttranslational modifications, and dysregulation of protein kinases
is associated with the pathogenesis of different diseases. Therefore, interest in developing potent
small molecule kinase inhibitors has increased enormously within the last two decades. A critical
step in the development of new inhibitors is cell-free in vitro testing with the intention to determine
comparable parameters like the commonly used IC50 value. However, values described in the
literature are often biased as experimental setups used for determination of kinase activity lack
comparability due to different readout parameters, insufficient normalization or the sheer number
of experimental approaches. Here, we would like to hold a brief for highly sensitive, radioactive-
based in vitro kinase assays especially suitable for kinases exhibiting autophosphorylation activity.
Therefore, we demonstrate a systematic workflow for complementing and validating results from
high-throughput screening as well as increasing the comparability of enzyme-specific inhibitor
parameters for radiometric as well as non-radiometric assays. Using members of the CK1 family of
serine/threonine-specific protein kinases and established CK1-specific inhibitors as examples, we
clearly demonstrate the power of our proposed workflow, which has the potential to support the
generation of more comparable data for biological characterization of kinase inhibitors.
Keywords: protein kinase; small molecule inhibitor; IC50; inhibitor constant; Ki; workflow; standard-
ization; CK1
1. Introduction
Posttranslational modifications of proteins are manifold and can be linked to various
functional consequences for the mature polypeptide like the regulation of protein activity
or stability. One of the most common posttranslational modifications is the phospho-
rylation of proteins. Protein kinases catalyze the reversible transfer of an ATP-derived
γ-phosphate moiety to a substrate protein, either resulting in its activation, deactivation or
even degradation [1,2]. Therefore, phosphorylation represents one of the most important
regulatory mechanisms for cellular processes like protein synthesis, cell division or cell
adhesion [3,4]. As a consequence, dysregulation of protein phosphorylation can be linked
to the pathogenesis of various diseases, among others inflammatory, cardiovascular, and
neurodegenerative diseases as well as cancer [5,6]. Within the past two decades, protein
kinases attracted major attention as targets for inhibition mediated by small molecule
inhibitors (SMIs). To date more than 100,000 SMIs for protein kinases have been described
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and characterized [7], from which 76 already have been approved by the local state authori-
ties. However, in cancer research only 50 of the more than 500 human protein kinases have
been exploited as drug targets so far [8].
A critical step in the development of new SMIs is the cell-free in vitro testing of novel
inhibitor compounds with the intention to determine the IC50 values (concentration for
50% inhibition), specified by the amount of inhibitor required to reduce total enzyme
activity by 50%. Although IC50 values as empirical values are generally established to
compare the potency of SMIs, literature-derived values are often biased as kinase assays
used for the determination of kinase inhibitory effects lack comparability due to varying
experimental setups including different readout parameters or insufficient normalization.
Thus, the use of IC50 values is only useful for quick comparison of various compounds
tested in the same experimental setup, but it is inappropriate to compare data generated
in different laboratories using different assay strategies. This lack of comparability can be
overcome by using Ki, an enzyme-specific variable that is independent of the experimental
setup and universally comparable. Determining Ki can be difficult and never infallible,
but extrapolating Ki from IC50 values of kinase inhibitors significantly contributes to
comparability. As an example for the lack of comparability, IC50 values determined for
established CK1-specific inhibitors are shown in Table 1.
Table 1. Interlab variation of IC50 values for CK1-specific inhibitors.
Working Group A Working Group B
Inhibitor IC50 [µM] ATP [µM] Isoform Ref. IC50 [µM] ATP [µM] Isoform Ref.
IC261 1 10 CK1δ [9] 2.5 100 CK1δ ** [10]
D4476 0.3 20 CK1δ * [11] 0.2 100 CK1δ ** [10]
PF-670462 0.008 5 CK1ε * [12] 0.08 10 CK1ε [13]
* Use of C-terminally truncated kinases (CK1δ(1–294) and CK1ε∆319, respectively). ** Use of CK1δ of yeast origin
(Saccharomyces pombe). IC50, concentration for 50% inhibition.
In vitro kinase reactions are usually composed of recombinantly produced kinases
used to phosphorylate either peptide or protein substrates. Not only the origin (e.g.,
human vs. yeast), the manufacturing process of the kinase protein (e.g., prokaryotic vs.
eukaryotic expression systems, expression time, temperature during protein expression,
purification via His vs. GST tag), or the presence of organic solvents (e.g., DMSO), but
also the reaction conditions and readout technique selected to determine the parameters of
the enzymatic reaction can be highly variable. In recent years, various label-free methods
have been developed to determine kinase activity in vitro, including colorimetric, fluori-
metric and mass spectrometry-based approaches, with readouts more approachable for
high-throughput screenings as meanwhile also offered by numerous contract research
organizations (CROs) [14]. Most of these approaches are designed to measure consumption
of the co-substrate ATP or to determine the generation of ADP [15,16]. As different label-
ing strategies are used in high-throughput applications, an attenuation of accuracy and
comparability has to be considered. Hence, the validation of high-throughput inhibitor
data, comparable to the validation of mRNA microarray data by qRT-PCR results, seems to
be indispensable in this field of research. This validation can be achieved by performing
highly accurate, enzyme-optimized radiolabeling assays. In contrast to fluorescence- and
luciferase-based kinase assays, phosphorylation of the substrate protein can be directly
measured after providing radioactively labeled [γ-32P]-ATP or [γ-33P]-ATP as co-substrate
to the kinase to be analyzed and by detecting incorporation of radioactively labeled phos-
phate into the substrate. Although working with radioactive substances is often considered
as outdated and cumbersome, the high tractability and sensitivity of radiolabeled assays
are among their major advantages. Further advantages are the use of any reaction solvents,
natural substrates, a wide range of substrate concentrations, cell lysates, the possibility to
identify specific phosphorylation sites and the direct validation of detected site-specific
phosphorylation events by using phosphorylation-site substrate mutants. Lastly, the sub-
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sequent separation of the kinase reactions via SDS-PAGE also allows for discrimination
between substrate phosphorylation and autophosphorylation of the kinase protein, which
is essential in order to correctly and reliably determine kinase activity and thus inhibitor
potency. Autophosphorylation modulates kinase activity and is a feature shared by al-
most all eukaryotic protein kinases [17,18], most of them becoming catalytically active
by phosphorylation of their activation loop or autophosphorylation domains [19]. The
levels of kinase autophosphorylation can be highly variable between kinases originating
from different expression systems [20]. In case of auto-activating kinases different au-
tophosphorylation levels can be overcome by preincubation with ATP prior to performing
in vitro kinase assays with exogenous substrates. Unfortunately, a reliable pretreatment for
auto-inactivating kinases, like CK1, does not exist and is limited to hardly reproducible
procedures involving co-expression of or treatment with phosphatases [21]. Alternatively,
autophosphorylation sites could be mutated or autophosphorylation domains truncated,
however, resulting in artificially activated kinase proteins with disturbed sequence in-
tegrity [22,23]. Precisely for that reason autophosphorylation, disregarded by most of the
commonly available screening methods, should be investigated prior to inhibitor testing
and treated as an additional variable that can highly influence and distort results. Apart
from the methods specifying the readout parameters for the assays, important basics of
enzyme kinetics have to be taken into account when determining comparative values (e.g.,
IC50) for SMIs [24]. These include (i) the determination of the initial velocity region of
the enzymatic reaction and (ii) the determination of the Michaelis constant (Km) and the
inhibitor constant (Ki) under the previously determined initial velocity conditions.
1.1. Determination of the Initial Velocity Region
For an enzymatic reaction, the initial velocity region describes the linear part of a
product-over-time progression curve characterized by time-dependent increase in pro-duct
concentration and a constant slope indicating the highest possible enzyme velocity [24].
With increasing time, the enzyme velocity (the slope of the progression curve) decreases
due to a lack of substrate (Figure 1 black curve). By decreasing the enzyme concentration
(red curve) the initial velocity region can be extended while simultaneously lowering the
limit of detectable IC50 values. The shape of the initial velocity region can furthermore be
affected by the loss of enzymatic activity due to inhibition (e.g., mediated by autophospho-
rylation [18], product inhibition [25]) or degradation (green curve). Determining the initial
velocity region by testing different enzyme concentrations is a mandatory requirement for
the correct subsequent determination of the kinetic parameters and should be considered
as the first step of the inhibitor screening procedure. Ideal enzyme concentration and
reaction time should be selected from the initial velocity region within a period in which
no more than 10% of the total substrate concentration has been consumed [24]. By default,
the defined enzyme concentration and reaction time should be used for the subsequent
experiments.
Figure 1. Exemplary product-over-time progression curves for an exemplary enzymatic reaction.
The product-over-time curves are shown for different conditions including different enzyme con-
centrations ([E] and [E]/2 shown in black and red) and inhibited or degraded enzyme (green). [E],
enzyme concentration.
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1.2. Determination of Km (ATP) and Ki under Initial Velocity Conditions
The potency of SMIs acting on various target enzymes is usually compared on the
basis of their respective IC50 values. However, due to the use of different reaction setups,
comparability of IC50 values can be limited and using the enzyme-specific Ki instead is
considered to be advantageous. In order to calculate the Ki value, determination of the
Km for ATP has to be performed first. Therefore, the previously defined initial velocity
conditions (enzyme concentration and reaction time) are used for testing different ATP
concentrations ranging from 0.5 to 5 times Km while maintaining the substrate to be phos-
phorylated under saturating conditions. Testing new enzymes with an unknown Km value
should follow an iterative process where the compliance of the ATP concentration range
is subsequently evaluated and re-adjusted, if necessary. Km (ATP) serves as an important
reference value for the ATP concentration to be used in subsequent kinase assays for IC50






For competitive inhibitors Kic can easily be calculated if the used ATP concentration
[S] in IC50 kinase reactions equals the Km (ATP):
[S] = Km (2)
In this case, Equation (2) can be substituted into Equation (1) and Kic can be defined





Consequently, using an ATP concentration equal to Km (ATP) under initial velocity
conditions allows for the direct conversion of the calculated IC50 into the enzyme-specific in-
hibitor constant Kic. Following the proposed workflow of determining the ideal enzymatic
reaction parameters, and by implementing an experimental setup meeting various impor-
tant requirements (summarized in Figure 2) it will be possible to determine enzyme-specific
values for the reliable comparison of inhibitor potency on different enzymes. Using protein
kinases of the CK1 family and several well-established CK1-specific SMIs as examples, we
demonstrate the implementation and the significance of the proposed workflow. Although
a radiometric determination approach is used in our demonstration, the workflow can
easily be adapted to non-radiometric assays.
Figure 2. Considerations and suggested workflow for in vitro kinase inhibitor characterization. (A) Apart from basic
considerations concerning the detection method to be used and the reaction conditions, also enzyme- and substrate-specific
characteristics need to be taken into account. (B) The suggested workflow consists of five steps resulting in generation of
major parameters essential to calculate Ki values, which can be easily used to compare inhibitory effects for various SMIs
and different enzymes.
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Members of the CK1 family and their respective splice variants are highly conserved
serine/threonine protein kinases involved in the regulation of several fundamental cellular
processes like stress response and cell cycle progression [27]. Due to their regulatory
function in DNA damage-related signal transduction including the direct phosphorylation
of central components like p53 and MDM2 as well as their involvement in Wnt, Hedgehog
and Hippo signal transduction pathways CK1 isoforms have evolved as potential targets
in cancer therapy [28,29]. Dysregulation and mutations of CK1 isoforms were shown
to be involved in cancer progression but also play a critical role in the development
of neurodegenerative diseases like Alzheimer’s disease [18,30]. According to this, the
development of SMIs that exclusively inhibit disease-associated CK1 isoforms has been
promoted in recent years.
2. Results
Demonstrating a workflow for the establishment of standardized and reproducible
kinase reactions and kinase inhibitor characterization, the considerations and processes
starting with the nature of recombinant kinase and finishing in the determination of IC50
or Kic values are exemplarily demonstrated for the inhibition of protein kinase CK1δ.
Simultaneously, the effects of different affinity tags, intramolecular autophosphorylation as
well as organic solvents is being investigated. Finally, the universality and transferability of
the proposed workflow as well as the superior comparability of Kic instead of IC50 values
is demonstrated by characterizing inhibitory effects of established inhibitors on another
CK1 isoform.
2.1. Determination of Initial Velocity Region for GST-Tagged CK1δ
In a first step the initial velocity region for GST-tagged CK1δ was determined by mea-
suring the time-dependent substrate phosphorylation of α-casein using different enzyme
concentrations (7, 70, and 335 nM) (Figure 3A). For the determination of the initial velocity
region, the phosphate donor ATP was used at a concentration of 10 µM (equal to 150 pmol
per reaction). Additionally, the influence of the inhibitor solvent DMSO was investigated
(Figure 3B,C). The corresponding time-dependent autophosphorylation of GST-tagged
CK1δwas determined by measuring phosphate incorporation into GST-CK1δ.
The time-dependent phosphorylation of α-casein, as well as the autophosphorylation
of GST-tagged CK1δ, show a typical time-conversion curve starting with a linear region
(initial velocity is maximal) and reaching a plateau at later time points. A statistically
significant influence of DMSO on phosphorylation of α-casein (Figure 3A) could only be
observed for the highest enzyme concentration (335 nM), whereas a statistically significant
interaction between the factors time and DMSO was observed for the autophosphorylation
level (Figure 3B) at the lowest enzyme concentration (7 nM). More importantly, proportional
autophosphorylation of GST-CK1δ showed a statistically significant increase with increas-
ing enzyme concentration (Figure 3C) making up about 40% of the total phosphorylation
within reactions containing the highest enzyme concentration (335 nM).
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Figure 3. Product-over-time progression curve for GST-tagged CK1δ autophosphorylation and substrate phosphorylation.
(A) Time-dependent phosphate transfer from [γ-32P]-ATP to the substrate α-casein catalyzed by human recombinant GST-
tagged CK1δ using different enzyme concentrations (7, 70, 335 nM) was determined by in vitro kinase reactions in absence
and presence of solvent (+/− DMSO). (B) Time-dependent autophosphorylation of GST-CK1δ has been determined and is
presented similar to data shown in (A). (C) The mean proportional autophosphorylation relative to total phosphorylation
(cumulated time-points) is significantly increased at higher enzyme concentrations. Statistical significance was tested using
two-way ANOVA (for data presented in (A,B)) and unpaired two-tailed t-test (C). ns indicates p > 0.05, ** indicates p ≤ 0.01,
*** indicates p ≤ 0.001, **** indicates p ≤ 0.0001. DMSO, dimethyl sulfoxide.
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Since SMIs characterized by in vitro kinase reactions are typically dissolved in DMSO,
the determination of the initial velocity region was exclusively conducted for kinase reac-
tions containing DMSO to maintain consistency of conditions. Apart from that, the lowest
enzyme concentration possible (enzyme concentration vs. signal intensity) was used to min-
imize the IC50 detection limit. According to data presented in Figure 3, a concentration of
7 nM of GST-CK1δ could be used as the signal to background (S/B) ratio obtained with
7 nM concentration was sufficient at each time point measured (S/B ratio ≥ 10). Linear
regression analysis with stepwise decreasing the number of included time points of the
product-over-time progression curve determined for GST-CK1δ indicated an optimal time
range of 10 min (n = 4, R2 = 0.99) (Figure 4). According to these results, subsequent de-
termination of Km (ATP) and IC50 values using GST-CK1δwas conducted with an enzyme
concentration of 7 nM and for a reaction time of 10 min.
Figure 4. Determination of initial velocity linear region for GST-CK1δ. (A) In order to determine the
maximum coefficient of determination (R2) linear regression analysis was conducted with stepwise
decreasing the number of included time points of the product-over-time progression curve deter-
mined for GST-CK1δ (7 nM). (B) Linear regression for the determined initial velocity region (10 min)
including R2 value and confidence bands (95%). n, sample size; R2, coefficient of determination.
2.2. Determination of Initial Velocity Region for 6×His-Tagged CK1δ
Similar to GST-tagged CK1δ, the initial velocity region as well as the optimal enzyme
concentration were determined for 6×His-tagged CK1δ. Simultaneously, autophosphory-
lation and the influence of DMSO were also assessed.
For the time-dependent phosphorylation of α-casein by 6×His-CK1δ as well as for
the time-dependent progression of autophosphorylation, the respective saturation curves
could be determined as expected (Figure 5A,B). However, a strong influence of DMSO
was observed for all tested enzyme concentrations. Additionally, as previously seen for
GST-CK1δ, the proportional autophosphorylation significantly increased with increasing
concentrations of 6×His-CK1δ making up about 30% of the total protein phosphorylation
within the kinase reactions at the highest enzyme concentration tested (335 nM). Also, for
6×His-CK1δ the lowest enzyme concentration possible (enzyme concentration vs. signal
intensity) was used to determine the initial velocity region (Figure 6). In the case of 6×His-
CK1δ, a concentration of 70 nM could be used as the signal to background ratio exceeded
a value of ten at each time point measured, which was not the case using an enzyme
concentration of 7 nM (S/B ratio at 2 min without DMSO = 5.1).
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Figure 5. Product-over-time progression curve for 6×His-tagged CK1δ autophosphorylation and substrate phosphorylation.
(A) Time-dependent phosphate transfer from [γ-32P]-ATP to the substrate α-casein catalyzed by human recombinant
6×His-tagged CK1δ using different enzyme concentrations (7, 70, 335 nM) was determined by in vitro kinase reactions
in absence and presence of solvent (+/− DMSO). (B) Time-dependent autophosphorylation of 6×His-CK1δ has been
determined and is presented similar to data shown in (A). (C) The mean proportional autophosphorylation relative on total
phosphorylation (cumulated time-points) is significantly increased at higher enzyme concentrations. Statistical significance
was tested using two-way ANOVA (for data presented in (A,B)) and unpaired two-tailed t-test (C). * indicates p ≤ 0.05,
*** indicates p ≤ 0.001, **** indicates p ≤ 0.0001. DMSO, dimethyl sulfoxide.
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Figure 6. Determination of initial velocity linear region for 6×His-CK1δ. (A) In order to determine
the maximum coefficient of determination (R2) linear regression analysis was conducted with step-
wise decreasing the number of included time points of the product-over-time progression curve
determined for 6×His-CK1δ (70 nM). (B) Linear regression for the determined initial velocity re-
gion (10 min) including R2 value and confidence bands (95%). n, sample size; R2, coefficient of
determination.
Stepwise decreasing linear regression applied on data of the obtained product-over-
time progression curve for 6×His-CK1δ indicated an ideal linear region between 5 and
10 min of reaction time. In order to obtain higher signal, an enzyme concentration of 70 nM
and 10 min reaction were used for subsequent experiments to determine the Km (ATP) and
IC50 values for 6×His-CK1δ.
2.3. Determination of Km under Initial Velocity Conditions
In order to determine the Km (ATP) values for GST-CK1δ and 6×His-CK1δMichaelis-
Menten enzyme kinetic analysis was performed under the defined initial velocity con-
ditions using varying ATP concentrations ranging from 0.5 to 100 µM (Figure 7). The
resulting Km (ATP) is defined as the concentration of the co-substrate ATP at which the
respective enzymatic velocity of GST-CK1δ or 6×His-CK1δ is half of its maximal value.
The calculated Km (ATP) for 6×His-CK1δ was 14 µM, whereas for GST-CK1δ, a Km (ATP)
value of 6 µM was determined by using 7 nM concentration of GST-CK1δ and 70 nM of
6×His-CK1δ in kinase reactions performed for 10 min (see data above for determination
of ideal/minimal enzyme concentration and initial velocity region). In order to simplify
the transformation of the IC50 to the Kic value according to the Cheng-Prusoff equation
(see introduction section for detailed explanation), ATP concentrations equivalent to the
calculated Km (ATP) values were used in subsequent experiments with the aim to determine
IC50 values.
Figure 7. Michaelis-Menten kinetics for GST-CK1δ and 6×His-CK1δ assayed in presence of in-
creasing ATP concentrations. Initial velocity (Vinit) [pmol/min] was determined at different ATP
concentrations (0.5 to 100 µM). Km (ATP) defines the concentration of the co-substrate ATP at which
half of the maximal velocity (Vmax) is achieved. Km (ATP), Michaelis constant for ATP.
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2.4. Determination of IC50 Values Using Adapted ATP Concentrations
According to our workflow with the aim of determining comparable parameters for
SMIs, IC50 values for GST-CK1δ and 6×His-CK1δwere determined using the defined initial
velocity conditions and an ATP concentration equivalent to the calculated Km (ATP) values.
As appropriate examples for previously reported and established SMIs the CK1-specific
ATP-competitive inhibitors PF-670462 [12] and Liu-20 [30] were used for determination of
IC50 values (Figure 8 and Table 2). The determined IC50 values show high comparability
between GST- and 6×His-tagged CK1δ: IC50 values were calculated with 69.85 nM (PF-
670462) and 395.80 nM (Liu-20) for GST-CK1δ and 64.18 nM (PF-670462) and 403.60 nM
(Liu-20) for 6×His-CK1δ.
Figure 8. IC50 values of inhibitors PF-670462 and Liu-20 for GST-CK1δ and 6×His-CK1δ. In vitro
kinase reactions were performed in presence of increasing concentrations (1 to 250 nM) of the
CK1-specific inhibitors PF-670462 and Liu-20 using GST-CK1δ (7 nM) or 6×His-CK1δ (70 nM) as
kinases. Kinase activity was determined by measuring phosphate incorporation into α-casein and
data analysis was performed as described in the materials and methods section. IC50, concentration
for 50% inhibition.
2.5. Determination and Comparison of Kic for GST-CK1δ and 6×His-CK1ε Using the CK1ε
Specific Inhibitor PF-4800567
In order to prove the concept of the suggested workflow and to demonstrate the
superior comparability of Kic values, the inhibitory potential of the CK1ε-specific inhibitor
PF-4800567 was determined using GST-tagged CK1δ and 6×His-tagged CK1ε. While the
initial velocity region (10 min at 70 nM enzyme concentration) and Km (ATP) (6 µM) for GST-
CK1δ have already been defined (see above) these parameters still had to be determined
for 6×His-CK1ε.
Because we expected a similar level of activity for 6×His-CK1ε as for the previously
tested 6×His-CK1δ, the same enzyme concentration of 70 nM was also used for 6×His-
CK1ε. As formerly demonstrated for GST- and 6×His-CK1δ, the solvent DMSO also
showed a significant influence on the time-dependent substrate phosphorylation by 6×His-
CK1ε (Figure 9A,B). Linear regression analysis with stepwise decreasing the number of
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included time points indicated an optimal time range of 5 min (R2 = 0.92) for the initial
velocity region as tested for 70 nM concentration of 6×His-CK1ε (Figure 9C). Consequently,
subsequent kinase reactions including the determination of the Km (ATP) and IC50 for 6×His-
CK1ε were conducted using an enzyme concentration of 70 nM and a reaction time of
5 min.
Table 2. Overview of the tested (A) enzymes and (B) inhibitors as well as the determined IC50 values and the resulting
Kic values.
(A)
Enzyme Inhibitor IC50 [nM] Kic [nM] IC50 in Literature [nM]
GST-CK1δ
PF-670462 69.85 34.93 13 * [13]
Liu-20 395.80 197.90 86 [30]
PF-4800567 2012.00 1006.00 711 * [13]
6×His-CK1δ PF-670462 64.18 32.09 -Liu-20 403.60 201.80 -
6×His-CK1ε PF-4800567 72.30 36.15 32 ** [13]
(B)
Inhibitor PF-670462 PF-4800567 Liu-20
Structure
Reference [12] [13] [30]
* IC50 values were determined using untagged CK1δ and a CK1-specific peptide substrate. ** IC50 value was determined using 6×His-CK1ε
and a CK1-specific peptide substrate. IC50, concentration for 50% inhibition; Kic, inhibitor constant (competitive inhibitor).
Michaelis-Menten kinetics for 6×His-CK1ε with varying concentrations of ATP re-
vealed a Km (ATP) value of 21 µM (Figure 9D). Consequently, subsequent determination of
IC50 values for the CK1ε-specific inhibitor PF-4800567 using GST-CK1δ and 6×His-CK1ε
was performed under the defined, enzyme-specific initial velocity conditions with an
ATP-concentration equivalent to the calculated Km value (see results presented above for
parameters specific for GST-CK1δ).
The IC50 value using the CK1ε-specific inhibitor PF-4800567 was calculated to be
2012 nM for GST-CK1δ and 72.3 nM for 6×His-CK1ε (Figure 10), thereby confirming the
inhibitor’s selectivity for CK1ε. Furthermore, the suggested workflow for determination
of highly comparable parameters for SMIs allows the conversion of the calculated IC50
values for all tested competitive CK1-specific inhibitors to Kic by implementing Equation
(3) as given in the introduction section. By providing Kic, the results will be made highly
comparable even among different enzymes. All IC50 values, which were determined in the
present study along with the resulting Kic values are summarized in Table 2. IC50 values
previously reported in literature are also included in Table 2. However, it is important
to note that these values cannot be easily compared to the values presented here due to
significant differences in their experimental and reaction setup (such as luminescent vs.
radioactive kinase assay, use of kinase proteins without or with different affinity tags, use
of protein or peptide substrates).
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Figure 9. Product-over-time progression curve for 6×His-tagged CK1ε and Michaelis-Menten
kinetics for 6×His-CK1ε assayed in presence of increasing ATP concentrations. (A) Time-dependent
phosphate transfer from [γ-32P]-ATP to the substrate α-casein catalyzed by human recombinant
6×His-tagged CK1ε using 70 nM enzyme concentration was determined by in vitro kinase reactions
in absence and presence of solvent (+/− DMSO). (B) Time-dependent autophosphorylation of
6×His-CK1ε has been determined and is presented similar to data shown in (A). (C) In order to
determine the maximum coefficient of determination (R2) linear regression analysis was conducted
with stepwise decreasing the number of included time points of the product-over-time progression
curve determined for 6×His-CK1ε (70 nM). Linear regression for the determined initial velocity
region (5 min) including R2 value and confidence bands (95 %) is presented in (C). (D) Initial velocity
(Vinit) [pmol/min] was determined at different ATP concentrations (0.5 to 100 µM). Km (ATP) defines
the concentration of the co-substrate ATP at which half of the maximal velocity (Vmax) is achieved.
Statistical significance was tested using two-way ANOVA (for data presented in (A,B). ns indicates
p > 0.05, * indicates p ≤ 0.05, ** indicates p ≤ 0.01, **** indicates p ≤ 0.0001. DMSO, dimethyl sulfoxide;
Km (ATP), Michaelis constant for ATP; n, sample size; R2, coefficient of determination.
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Figure 10. IC50 values of inhibitor PF-4800567 for GST-CK1δ and 6×His-CK1ε. In vitro kinase
reactions were performed in presence of increasing concentrations (1 to 250 nM) of the CK1ε-specific
inhibitor PF-4800567 using GST-CK1δ (7 nM) or 6×His-CK1ε (70 nM) as kinases. Kinase activity was
determined by measuring phosphate incorporation into α-casein and data analysis was performed
as described in the materials and methods section. IC50, concentration for 50% inhibition.
3. Discussion
In the present study by using the example of CK1, we presented a systematic workflow
for the in vitro characterization of SMIs with the aim to achieve more universal comparabil-
ity, even between different tested enzymes. Thorough determination of the initial velocity
region as well as defining an ATP concentration equal to Km (ATP) enables the conversion of
the obtained IC50 values to the inhibitor constant Ki, an enzyme-specific variable that is
independent of the experimental setup and universally comparable.
In general, certain considerations need to be made before setting up screening ap-
proaches to determine kinase activity and inhibitory potency of SMIs. As mentioned earlier,
variability in protein kinase purification approaches (GST vs. 6×His affinity tag) or the
effects of intramolecular autophosphorylation need to be taken into account. While per-
forming this study, we showed that autophosphorylation of CK1δ is significantly increased
at higher enzyme concentrations. Consequently, problems may arise using luci-ferase-
based kinase assays, which measure consumption of the co-substrate ATP or the generation
of ADP in general, and thus do not differentiate between phosphorylation events asso-
ciated with substrate phosphorylation or autophosphorylation [15,16]. With the enzyme
concentrations used in this study, substrate phosphorylation is overestimated with an
error of 36% (335 nM GST-CK1δ) or 26% (335 nM 6×His-CK1δ, see data presented in
Figures 3 and 5) when phosphorylation is not differentiated and autophosphorylation is
included in measurement of total phosphorylation events. Therefore, we propose to use
kinase assay setups, like the herein described radioactive based assay, allowing distinctions
between kinase autophosphorylation and substrate phosphorylation to minimize false pos-
itive signals. By separating kinase reactions in SDS-PAGE and subjecting excised protein
bands to Cherenkov counting, substrate phosphorylation and autophosphorylation can be
clearly distinguished. However, we are aware of the limitations of the in vitro kinase assay
using radiolabeled [γ-32P]-ATP such as exposure to radioactivity, the elaborate disposal of
radioactive waste and the use of protein substrates instead of easy to use peptide substrates.
Nevertheless, the high sensitivity and significant signal-to-noise ratio of the radioactive
based method enables the use of low enzyme concentrations. This is indispensable for the
investigation of highly effective inhibitors as the kinase concentration defines the lower
limit of detectable IC50 value by half of the used enzyme concentration (assumed that
the inhibitor binds to the kinase proteins in a one-to-one ratio) [31]. However, the lowest
enzyme concentration possible also needs to be selected based on a beneficial signal-to-
noise ratio and only enzyme concentrations resulting in clearly detectable phosphorylation
signals should be chosen for subsequent analysis.
In addition, we observed that the presence of DMSO significantly affected the mea-
sured enzyme activity up to 50%, as observed for 6×His-CK1δ. This influence of DMSO on
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enzyme activity showed that consideration of the experimental setup (solvents, buffers, pH)
is pivotal for enzyme kinetics and should be kept constant throughout the experimental
workflow, otherwise it is likely to falsifying the results. One should point out, that most
organic compounds like SMIs are dissolved in the organic solvent DMSO, which has to
be considered in the assay composition even in the initial experiments to eradicate this
potential source of error [32]. Although DMSO still is generally considered an irreplace-
able solvent, it might also be worthwhile to consider alternatives like zwitterion liquid
(ZIL), which recently has been characterized as multifunctional and biocompatible solvent
compensating many shortcomings noticed for DMSO [33].
The first part of the proposed workflow aims to determine the initial velocity region of
the enzyme reaction as well as the optimal enzyme concentration. As a basic principle, one
should realize that the lower detection limit of the IC50 to be determined is restricted by
the used enzyme concentration. When testing highly potent inhibitors, the lowest possible
enzyme concentration should be used, still maintaining a proper signal-to-noise ratio.
Although depletion of ATP catalyzed by all tested enzymes was less than 10% of total ATP
after 60 min, the reaction velocity already decreased after 10 min (as shown for 7 nM GST-
CK1δ and 70 nM 6×His-CK1δ in Figures 3 and 5) or 5 min (as shown for 70 nM 6×His-CK1ε
in Figure 9). Since substrate depletion cannot explain the decline in reaction velocity, CK1δ
might be inhibited due to time-dependent increase in autophosphorylation [18,34,35]. Un-
fortunately, autophosphorylation events within the enzyme reaction cannot be prevented
in an easy way, e.g., by the addition of phosphatases.
As a final step in our in vitro kinase assay workflow, we determined the IC50 values
of the published compounds PF-670462 and Liu-20 using two different recombinantly
expressed and purified enzymes, GST-CK1δ and 6×His-CK1δ. Under the conditions,
which were determined in previous experiments (initial velocity region, optimal enzyme
concentration, ATP concentration at Km (ATP)), the IC50 determination for the selected
inhibitors showed similar values for both differently purified and affinity-tagged CK1δ
kinases. In our case, the influence of different affinity tags was negligible, as can be seen
from the highly similar IC50 and Kic values determined for GST-CK1δ and 6×His-CK1δ
(see Table 1). However, the effects of used affinity-tags might have to be determined in a
kinase- or experiment-specific fashion.
When comparing the IC50 data provided in Table 2, it has to be considered that, as
expected, our calculated IC50 values for PF-670462, Liu-20 and PF-4800657 differ from the
previously published IC50 values of 13 nM for PF-670462 and CK1δ [13], 86 nM for Liu-
20 [30], 711 nM for PF-4800567 and CK1δ as well as 32 nM for PF-4800567 and CK1ε [13]
(see Table 2). Apart from the possible occurrence of batch-to-batch variability for the tested
SMIs (which is beyond the scope of this manuscript and will not be discussed further),
these differences might arise because the initial velocity region for performing in vitro
kinase reactions has not been determined properly, or a differentiation between substrate
phosphorylation and autophosphorylation has not been possible due to assay design
and the analysis of total phosphorylation events, as this was the case for the previous
determination of IC50 values for PF-670462 and PF-4800567 [13]. For determining these
values, a luminescence-based assay setup detecting remaining ATP levels in the kinase
reactions was used [13]. Furthermore, discrepancies in IC50 values might also arise from
different ATP concentrations used in different experimental setups. While this was not the
case for the original data reported for Liu-20, PF-670462 and FP-4800567 (all tested at 10 µM
concentration [13,30]), this is a common problem observed in literature (reviewed for CK1-
specific inhibitors in [29]). Instead of using arbitrary ATP concentrations for in vitro kinase
reactions, inhibitors should be tested at ATP concentrations equal to Km (ATP) for the enzyme
to be tested, as suggested by our workflow. Finally, in order to ensure comparability of the
parameters describing inhibitor potency between different inhibitors and enzymes, the Ki
value should be determined and stated by default. In our presented example experiments
and calculations, only ATP-competitive CK1-specific inhibitor compounds were used,
for which Equation (3) for competitive inhibitor binding can easily be implemented to
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determine Kic. However, while concentration-specific effects of kinase, substrate and ATP
are already considered when calculating Ki or can be neglected, the types of kinase protein
(e.g., clear designation of isoforms and splice variants or the use of truncated proteins)
and substrate to be phosphorylated need to be provided when describing the performed
kinase reactions. In the case of CK1δ, it has to be considered that the C-termini of the
various splice variants differ in length, sequence and their site-specific phosphorylation
pattern [28]. Due to its influence on kinase conformation and activity this difference also
influences IC50 and Ki values [36,37].
4. Material and Methods
4.1. Expression and Purification of GST-Tagged CK1δ
Expression of recombinant GST-human CK1δ (transcription variant 1; NM_001893 [38])
was induced by adding 1 mM IPTG to diluted overnight bacteria cultures at an OD600
of 0.7 to 0.9 AU. After protein overexpression for 18 h at 18 ◦C bacteria cultures were
harvested by centrifugation. Bacteria pellets were stored at −80 ◦C until further use.
Bacteria cell lysis was performed by using lysozyme in GST lysis buffer (20 mM Tris-HCl
(pH 7.6), 150 mM NaCl, 10% [v/v] glycerol, 0.5% [v/v] NP40, 1 mM EDTA, 1 mM EGTA,
1 mM benzamidine, 1 mM aprotinin, 1 mM DTT) on ice for 30 min. Bacterial DNA was
fragmented via ultrasonic sound treatment (Thermo Fisher Scientific Inc., Waltham, MA,
USA). The lysate was cleared by centrifugation at 10,000 rpm and 4 ◦C for 30 min. Using
an automated FPLC system (EttanLC, GE Healthcare, Chalfont St Giles, GB) the filtered
supernatant was loaded onto an equilibrated GSTrap FF 1 mL column (Cytiva, Freiburg,
Germany) at a flow rate of 0.5 mL/min. Column was washed with lysis buffer until UV
detection at 280 nm reached a stable baseline. Column-bound protein was eluted stepwise
using elution buffer (50 mM Tris-HCl (pH 7.6), 5 mM reduced glutathione, 1 mM EDTA)
and eluted protein was finally dialyzed against glutathione-free elution buffer three times
for 10 min each.
4.2. Expression and Purification of 6×His-Tagged CK1δ and 6×His-Tagged CK1ε
Expression and harvest of bacterial cultures of recombinant 6×His-human CK1δ
(transcription variant 1; NM_001893 [38]) and 6×His-human CK1ε (transcription variant
1; NM_152221 [39]) were performed as indicated above for GST-CK1δ. Bacteria cell lysis
was performed as mentioned above by using 6×His lysis buffer, which is composed of
20 mM Tris-HCl (pH 7.6), 150 mM NaCl; 10 % [v/v] glycerol, 1 mM benzamidine and 1 mM
aprotinin. Cleared and filtered lysate was loaded onto cOmpleteTM His-Tag purification
1 mL column (Roche, Mannheim, Germany) at a flow rate of 0.5 mL/min. The column
was washed with a gradient from lysis buffer to of washing buffer (20 mM Tris-HCl (pH
7.6), 50 mM NaCl, 10% [v/v] glycerol, 1 mM aprotinin) at 0.5 mL/min within 30 min.
Afterwards, proteins were eluted with a gradient from washing buffer to 6×His elution
buffer (20 mM Tris-HCl (pH 7.6), 250 mM imidazole) within 3 min. Eluted protein was
dialyzed against imidazole-free elution buffer three times for 10 min each.
4.3. In Vitro Kinase Reactions
All in vitro kinase reactions were performed at 30 ◦C in a total volume of 15 µL con-
taining 25 mM Tris-HCl (pH 7.0), 10 mM MgCl2, 100 µM EDTA and 0.4 pmol [γ-32P]-ATP.
Substrate (α-casein) was used at 2.5 (initial experiments) or 10 µM (IC50 determination)
and ATP concentrations were used within a range from 0.5 to 100 µM, respectively, de-
pending on the experimental setup. GST- or 6×His-tagged CK1δ or CK1ε were used as
enzymes in 7, 70 or 335 nM concentration. Additionally, a reaction without enzyme was
performed and used to determine the background signal specifying the minimal usable
enzyme concentration (signal to background ratio ≥10). Reactions were stopped by adding
3 µL of 5× SDS loading buffer and boiling at 95 ◦C for 5 min. Proteins were separated by
SDS-PAGE and stained with Coomassie Brilliant Blue R250 (Waldeck GmbH & Co. KG,
Muenster, Germany). Radioactively labelled proteins were visualized by autoradiography.
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For quantification, phosphorylated proteins were excised from dried gels and phosphate
incorporation was measured via Cherenkov counting.
For the determination of Vmax and Km, various ATP concentrations in a range from
0.5 to 100 µM were tested. Raw data was used to calculate enzyme velocity (V) (phosphate
transfer per min). V was plotted over ATP concentration and fitted to the Michaelis-Menten
model using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). Km was calculated
as the concentration of substrate needed to get half-maximal velocity. In order to determine
IC50 values, raw data was transformed from initially measured cpm values to pmol of
transferred phosphate. Subsequently data was transformed logarithmically (X = log(X)),
normalized to DMSO (100%) and zero (0%) and finally fit to sigmoidal dose-response
curves (variable slope) with nonlinear regression using GraphPad Prism 7.
4.4. Statistical Analysis
All measurements were carried out as triplets (n = 3). Outliers based on techni-
cal errors were removed and excluded from statistical analysis by visual inspection of
data. Comparison of the product-over-progression curves was performed with a two way
ANOVA (GraphPad Prism 7) to determine the influence of the factors time and DMSO,
as well as their interaction. Comparison between proportional autophosphorylation was
performed with an unpaired two-tailed t-test (α = 0.05, homogeneity of variances) or with
an unpaired two-tailed t-test with Welch’s correction (α = 0.05, heterogeneity of variances)
after normal distribution was confirmed (Shapiro-Wilk).
5. Conclusions
The increasing importance of protein kinases in several pathological conditions led to
the development of highly active SMIs with the intention to find novel ways of treatment.
The continuous improvement of lead structures is one of the key steps in the development
process of SMIs and is based on the results gained from in vitro kinase assays. However, a
lack of comparability due to interlaboratory variation evoked by unstandardized methods
and the implementation of high-throughput screenings, based on different assay formats
strongly affects the progress made in this field of research. Herein we provided a workflow
for verification and validation of high-throughput screening data as well as reduction of
interlaboratory variation.
The main and basic step of this workflow is the initial characterization of the enzyme
used in the assay by determination of the optimal enzyme concentration combined with
the definition of the initial velocity region. Further, after determining the Km value for ATP
the IC50 value of the inhibitors to be tested can be determined using the previously defined
conditions. As a proof of principle by following this procedure, we were able to generate
highly comparable Ki values using two SMIs (PF-670462 and Liu-20) and two different
tagged variants of CK1δ (GST vs. 6×His) from independent batches and purification
procedures mimicking two different working procedures from two different laboratories.
Furthermore, we demonstrate that enzyme-specific properties like autophosphorylation
or reaction-specific conditions like solvents (DMSO) can strongly falsify the results of
the assay. Therefore, understanding and evaluating the impact of these variables on the
enzyme reaction is a mandatory element in the procedure of standardization and should
not be neglected.
Although the assay conditions described in the present study were optimized for
CK1, the proposed systematic workflow can easily be established for any other enzymes
or substrates independently of the assay design. The implementation of a standardized
workflow for kinase reactions and inhibitor characterization allowing the presentation of
results with the aid of Ki instead of an IC50 value highly facilitates the comparability and
ranking of different SMIs, thereby providing superior efficiency for the in-silico modeling
and subsequent in vitro characterization of new inhibitor compounds.
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